Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has dropped 1.2%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves focusing on companies that can sustain robust revenue expansion and innovation despite short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.13%	24.28%	★★★★★★
Ardelyx	22.86%	54.70%	★★★★★★
AVITA Medical	33.33%	51.81%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Alnylam Pharmaceuticals	21.39%	56.40%	★★★★★★
TG Therapeutics	30.33%	44.07%	★★★★★★
Bitdeer Technologies Group	50.82%	122.48%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Blueprint Medicines	22.66%	55.14%	★★★★★★
Travere Therapeutics	29.92%	61.97%	★★★★★★

Click here to see the full list of 228 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Bitdeer Technologies Group (NasdaqCM:BTDR)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bitdeer Technologies Group operates as a technology company specializing in blockchain and computing, with a market cap of $2.81 billion.

Operations: The company generates revenue primarily from its data processing segment, amounting to $395.61 million. The business focuses on blockchain and computing technologies, contributing significantly to its operations and financial results.

Bitdeer Technologies Group, amidst a challenging landscape marked by a recent decline in Bitcoin mined and significant net losses, still showcases potential with an expected revenue surge of 50.8% annually. This growth trajectory is notably more robust than the broader US market's forecast of 9% per year. Despite current unprofitability, projections indicate Bitdeer could shift to profitability within three years, with earnings potentially escalating by 122.5% annually. The firm's aggressive R&D investment aligns with its innovation drive but requires careful monitoring as it navigates through financial volatility and operational adjustments evident from its strategic shelf registration and fixed-income offerings aimed at bolstering capital structure.

• Navigate through the intricacies of Bitdeer Technologies Group with our comprehensive health report here.

• Gain insights into Bitdeer Technologies Group's past trends and performance with our Past report.

TG Therapeutics (NasdaqCM:TGTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that specializes in developing and commercializing novel treatments for B-cell mediated diseases, with a market cap of approximately $4.27 billion.

Operations: TG Therapeutics focuses on the development and commercialization of innovative treatments for B-cell mediated diseases, generating revenue primarily from its biotechnology segment with $264.79 million. The company operates both in the United States and internationally, contributing to its market presence in the biopharmaceutical sector.

TG Therapeutics, amid a challenging financial landscape with recent quarterly revenue dropping to $83.88 million from the previous year's $165.82 million, still projects robust growth with expected annual revenue surging by 30.3%. The company's strategic focus on BRIUMVI U.S., anticipated to generate approximately $525 million in 2025, underscores its commitment to expanding its market footprint. Additionally, the firm has actively repurchased shares worth $2.15 million, reflecting confidence in its future prospects despite current unprofitability and a significant reduction in net income from $113.93 million to just $3.88 million year-over-year for the same quarter. This blend of aggressive revenue targets and share buybacks illustrates TG Therapeutics' proactive approach in navigating its turnaround phase while investing heavily in growth opportunities.

• Click here to discover the nuances of TG Therapeutics with our detailed analytical health report.

• Evaluate TG Therapeutics' historical performance by accessing our past performance report.

Cellebrite DI (NasdaqGS:CLBT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cellebrite DI Ltd. provides digital intelligence solutions for legally sanctioned investigations across various regions including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific with a market cap of $4.86 billion.

Operations: Cellebrite DI generates revenue primarily from its Internet Software & Services segment, amounting to $371.61 million. The company's operations focus on developing digital intelligence solutions for investigations across multiple global regions.

Cellebrite DI, navigating a transformative landscape in digital forensics, is poised for significant strides with a forecasted revenue growth of 14% annually. Despite current unprofitability, the firm's strategic pivot to a subscription model and integration of AI-driven platforms signal robust future profitability, anticipated to surge by an impressive 87.2% per year. This evolution is underpinned by substantial R&D investment, crucial for maintaining technological leadership in a rapidly advancing sector. The recent appointment of tech veteran Michael D. Capellas to the board underscores a strengthened governance structure poised to drive these innovations forward effectively.

• Click here and access our complete health analysis report to understand the dynamics of Cellebrite DI.

• Review our historical performance report to gain insights into Cellebrite DI's's past performance.

Key Takeaways

• Explore the 228 names from our US High Growth Tech and AI Stocks screener here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com